SFS
ACRS icon

Sowell Financial Services’s Aclaris Therapeutics ACRS Stock Holding History

Sowell Financial Services’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-400
Closed -$1K – 2396
2019
Q4 		$1K Hold
400
– – ﹤0.01% 2279
2019
Q3 		$0 Buy
+400
New +$567 ﹤0.01% 2382

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Sowell Financial Services's ACRS Position: Q1 2020 in Review

Sowell Financial Services sold out of Aclaris Therapeutics (ACRS) in Q1 2020, closing a stake of 400 shares — an estimated $1K sold.

Sowell Financial Services first reported a position in ACRS in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q4 2019. 71 funds tracked by Wall St. Rank hold ACRS as of Q1 2020.

  • Sowell Financial Services reported no remaining Aclaris Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Sowell Financial Services sold 400 Aclaris Therapeutics shares in Q1 2020, an estimated $1K.
  • Sowell Financial Services first reported a position in Aclaris Therapeutics in Q3 2019 and held it in 2 quarters.
  • Sowell Financial Services's Aclaris Therapeutics position peaked at $1K in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2020.

Based on Sowell Financial Services's 13F filing for Q1 2020, filed 12 May 2020.